|
Dr. Heimfeld is an Associate Faculty Member and serves as the Laboratory Director of the Cellular Therapy and cGMP Cell Processing Facilities at the Fred Hutchinson Cancer Research Center in Seattle Washington. He has a broad range of research interests with a particular focus on the development of improved therapeutic strategies using various human stem cell populations. His long-term goals for this area are to identify better markers for the characterization of stem and progenitor cells to improve isolation technologies for enriching these types of cells and to develop ex-vivo manipulation strategies that can enhance the therapeutic potential of these cells. Dr. Heimfeld has also been involved in the development of T-cell based immunotherapy for various diseases. Dr. Heimfeld currently serves as President-elect for ISCT (International Society of Cellular Therapy). He is also on the Board of Directors for FACT (Foundation for the Accreditation of Cellular Therapy) and is a leading authority in GLP GTP and GMP regulations working with the FDA to facilitate exchange of ideas in the rapidly evolving area of Cell Therapy. Dr. Heimfeld received his Ph.D. in Cell Differentiation from the University of California Irvine.
| 